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Adiponectin and renal 
disease progression: Another 
epidemiologic conundrum?
C Zoccali1 and F Mallamaci1
In an analysis based on the Mild to Moderate Kidney Disease (MMKD) 
study, adiponectin, a pleiotropic, insulin-sensitizing, anti-inflammatory 
and vasculo-protective cytokine, was directly related to renal disease 
progression. The precise definition of this apparently paradoxical 
association now requires that the research focus be moved from the 
study database to the experimental laboratory.
Kidney International (2007) 71, 1195–1197. doi:10.1038/sj.ki.5002319
An interesting observational study by 
Kollerits et al.1 (this issue) shows for the 
first time that adiponectin (ADPN) is 
a direct predictor of renal disease pro-
gression in male patients. As ADPN is 
a pleiotropic, insulin-sensitizing, anti-
inflammatory and vasculo-protective 
cytokine, these results are apparently 
counterintuitive with respect to biological 
eff ects of this peptide. Th is study off ers a 
stimulating starting point for discussing 
the use of observational studies in the 
complex process of causality assessment 
and for focusing on the fundamental 
importance of the clinical context wherein 
a given risk factor is being tested.
Observational studies and etiologic 
research
The problem of causality is central to 
clinical medicine. Inferring the cause 
of a given disease is a creative process 
based on conjectures and refutations that 
requires a variety of scientifi c verifi cations, 
including epidemiologic and experimen-
tal studies.2 Th e concept of risk factor for 
the study of multifactorial diseases such 
as hypertension, atherosclerosis, and 
chronic kidney disease (CKD) was devel-
oped about 50 years ago by investigators 
of the Framingham study. Th is concept 
is now used both to explore the causes of 
diseases (etiologic research) and to esti-
mate the probability of adverse outcomes 
(prognostic research). Although based on 
common statistical techniques, these two 
types of research are conceptually much 
diff erent. When we test the association of a 
putative risk factor — for example, ADPN 
— as a causal risk factor for renal disease 
progression (etiologic research), we ought 
to establish whether this association is 
independent of other risk factors; that is, 
we ought to exclude that the association 
is spurious because of the link of ADPN 
with other well-known risk factors. To 
this end, the clinical investigator and the 
biostatistician construct multivariate mod-
els that allow control for confounding by 
other risk factors. Th is approach is similar 
to that applied by a scientist who tests the 
eff ect of ADPN in experimental animals. 
In such an experiment, animals randomly 
receive either ADPN or an inert substance 
(control group). If properly performed, 
an experiment of this kind can isolate the 
eff ect of ADPN from other factors, because 
randomization equalizes both known and 
unknown risk factors, excluding ADPN, 
among the experimental animals; that is, 
randomization produces groups that, on 
average, have very similar blood pres-
sure, cholesterol, renal function, and so 
on. When all risk factors are similar, the 
outcome is determined only by the experi-
mental maneuver, that is, by exposure or 
lack of exposure to ADPN. Likewise, in 
prospective cohort studies, multivari-
ate analysis makes it possible to set all 
known risk factors but the factor being 
tested at the average value and to adjust 
the outcome accordingly. It is important to 
emphasize that, however accurate they can 
be, observational studies have the obvious, 
inherent limitation that they cannot con-
trol for unknown risk factors, a problem 
that can be resolved only with randomized 
experiments. It is worth mentioning that, 
whereas control for confounding is funda-
mental in etiologic research, confounders 
are absolutely not a problem in prognostic 
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research. Th e scope of prognosis is just that 
of predicting the outcome as accurately as 
possible on the basis of relevant etiologic 
risk factors and risk markers as well. In 
prognostic research the clinical epidemi-
ologist uses multivariate analysis not to 
adjust for confounding but to select the 
minimum set of risk factors (be they causal 
or non-causal) that eff ectively predicts the 
outcome. Here the scope of multivariate 
analysis is that of obtaining reliable and 
parsimonious models.
Framing the populating at risk: The 
experimental context is fundamental
In clinical medicine, some eff ects observed 
in a given context are not necessarily seen 
in other contexts. For example, sympatho-
lytic drugs with weak α1 agonistic activ-
ity, such as clonidine, consistently lower 
blood pressure in hypertensive patients 
but raise blood pressure in some patients 
with sympathetic failure and postjunc-
tional norepinephrine supersensitivity.3 
Similarly, in observational studies, a rela-
tionship between a predictor variable and 
an outcome variable in a given population 
may not be confi rmed or may even take an 
opposite direction in other populations. In 
individuals free of cardiovascular compli-
cations, the relationship between arterial 
pressure and cardiovascular risk is lin-
ear without evidence of a threshold. Th is 
relationship goes along with intervention 
studies showing that reducing the level of 
blood pressure lowers the risk of disease 
in hypertensive patients without obvious 
cardiovascular involvement. Yet, the con-
tinuous relationship between blood pres-
sure and cardiovascular events observed 
in hypertensive patients does not apply 
to other populations — for example, to 
populations with preexisting cardio-
vascular comorbidities. For example, in 
patients with heart failure, blood pressure 
is inversely rather than directly related to 
death.4 Th is is because low blood pressure 
in heart failure is a surrogate of pump 
failure, and therefore it is associated in an 
inverse fashion with mortality.
Adiponectin: Lights and shades of epide-
miologic studies
ADPN is an adipocyte-derived protein 
with antiatherogenic and anti-infl amma-
tory properties that is inversely related to 
fat mass and to body mass index (obese 
persons produce less ADPN than individu-
als with normal or low body weight). As is 
also discussed by Kollerits et al.,1 despite 
almost indisputable biological evidence that 
ADPN is a protective factor, prospective 
epidemiologic studies in the general popu-
lation and in patients with cardiovascular 
diseases produced apparently inconsist-
ent results. ADPN is increased in patients 
with CKD, particularly in those who reach 
end-stage renal disease. In end-stage renal 
disease patients, high ADPN predicted a 
lower risk for cardiovascular events.5 Th is 
association was interpreted as a compen-
satory response to infl ammation and/or 
malnutrition, an interpretation in keep-
ing with the fi nding that, independently 
of the glomerular fi ltration rate, ADPN is 
markedly increased also in patients with 
nephrotic syndrome.6 Similarly, in other 
analyses7 in the same CKD database inter-
rogated by Kollerits et al.1 (the Mild to 
Moderate Kidney Disease study database), 
high ADPN was associated with relatively 
higher insulin sensitivity and with a lower 
incident risk for cardiovascular disease, 
again suggesting a protective eff ect of this 
cytokine. In contrast, Menon et al.8 showed 
a direct rather than an inverse relationship 
between ADPN levels and mortality in 
patients with stage 3 and 4 CKD who took 
part in the Modifi cation of Diet in Renal 
Disease study.
These apparently conflicting results 
highlight some interpretative problems in 
etiologic research based on epidemiologic 
studies. Disparate results depend on the 
particular population being investigated, 
the case mix, and confounding by other risk 
factors that may be diffi  cult to control sta-
tistically. Th is is because the measurement 
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Figure 1 | Association of adiponectin with other risk factors and clinical outcomes. 
Upper panel: Summary of the relationship between adiponectin (ADPN) and some clinical 
characteristics. Lower panel: On biological grounds, the expected relationship between ADPN 
and clinical outcomes is an inverse one. However, this relationship may be confounded in a 
complex way by the presence of functional correlates of ADPN. Thus inflammation, malnutrition, 
and low glomerular filtration rate (GFR) (three obvious risk factors for adverse outcomes) tend 
to flatten, or even reverse the direction of, the association. However, the confounding effect of 
the GFR on plasma ADPN may almost completely disappear in end-stage renal disease patients, 
in whom the GFR nearly equalized to 0. ADPN resistance and secondary (counter-regulatory) 
hyperadiponectinemia would also tend to reverse this association. The prevalence and the 
functional effect of ADPN polymorphisms that influence plasma ADPN in the population under 
study and other factors (for example, prevalence of individuals with insulin resistance) may also 
influence the relationship between this cytokine and clinical outcomes. The final association 
depends on the clinical context wherein the association is tested (that is, on the presence or 
absence and the actual level of confounding variables). CRP, C-reactive protein; IL-6, interleukin-6.
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of these covariates is oft en imprecise, thus 
leaving substantial residual confounding. 
For example, in the study by Becker et al.,7 
the mean estimated glomerular fi ltration 
rate was 63 ml per minute and the mean 
ADPN 6 µmol per liter, compared with 
32 ml per minute and 12 µmol per liter in 
the study by Menon et al.8 Th e much lower 
ADPN in the fi rst of the two studies clearly 
reflects less severe renal insufficiency. 
Given the close association between ADPN 
and renal function, the direct relationship 
between ADPN and mortality in the study 
by Menon et al.8 may be due to residual 
confounding attributable to reduced renal 
function and/or to confounding by proc-
esses that accompany chronic renal diseases 
that are not captured by adjustment for the 
glomerular fi ltration rate. Furthermore, 
diff erential retention of high-molecular 
weight forms of ADPN in renal failure,9 the 
nutritional and infl ammatory status, poly-
morphisms in the gene encoding ADPN, 
and the various possibilities of combina-
tion of these factors may substantially alter 
the expected (inverse) relationship between 
ADPN and clinical outcomes (Figure 1). 
Causality assessment is a complex proc-
ess, and epidemiologic associations per se 
rarely if ever allow defi nitive conclusions 
on causality. Biological experiments and 
randomized experimental studies in ani-
mal models and in humans are needed to 
frame a reliable interpretation of such asso-
ciations. Yet the study by Kollerits et al.1 
is a very intriguing hypothesis-generating 
exercise, because, in a context where ADPN 
manifested its insulin-sensitizing and car-
diovasculo-protective properties (Becker 
et al.’s analysis in the same database7), it 
also displayed a clear-cut direct associa-
tion with a faster rate of renal disease pro-
gression. Th is is noteworthy because, in 
general, cardiovascular and renal damage 
proceed in parallel in patients with CKD. 
To explain their counterintuitive fi ndings, 
Kollerits et al.1 advance the hypothesis that 
in men with CKD there may be a condition 
of resistance to ADPN. However, because 
in this same cohort high ADPN was asso-
ciated with a lower incident cardiovascu-
lar risk,7 this hypothesis would imply that 
ADPN resistance in CKD patients is con-
fi ned to the kidney. Medical research dur-
ing the past century has been a to-and-fro 
process, from the bench to the bedside and 
vice versa. Given the therapeutic potential 
of increasing ADPN by pharmacologic 
intervention, the defi nition of the nature 
of the relationship between ADPN and 
progression of renal disease is a worthy 
scientifi c question. Th e precise defi nition 
of this association now requires that the 
research focus be moved to the experimen-
tal laboratory.
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Malignancy after kidney 
transplantation: Still a challenge
J-L Bosmans1 and GA Verpooten1
Long-term complications of continuous immunosuppression still remain 
a serious threat and are currently drawing the attention of transplant 
physicians. Wimmer et al. show that malignancy occurs approximately 
fourfold more frequently in renal-transplant recipients than in a normal 
control population.  Besides immunosuppression, viruses probably play 
an important oncogenic role in transplant recipients. The retrospective 
analysis by Wimmer et al. suggests that mTOR inhibitors and interleukin-2 
receptor antibodies are promising immunosuppressive drugs to reduce 
the risk of cancer after transplantation.  These preliminary results must be 
confirmed in large, prospective, randomized, controlled trials, with long 
follow-up, designed to evaluate the incidence of de novo malignancy in 
transplant recipients.
Kidney International (2007) 71, 1197–1199. doi:10.1038/sj.ki.5002306
Tremendous progress has been made in 
the fi eld of clinical transplantation since 
the fi rst kidney transplantation was per-
formed in 1954.1 Still, transplant physi-
cians are continually coping with the 
delicate balance between optimizing graft  
survival and reducing the side eff ects of 
immunosuppressive drugs, such as infec-
tions, malignancy, nephrotoxicity, and 
cardiovascular morbidity and mortality 
(Figure 1).
With the introduction of cyclosporine 
in the early 1980s, and tacrolimus, myco-
phenolate, interleukin-2 (IL-2) receptor 
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